Advisor Partners LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 8.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 60,635 shares of the company’s stock after purchasing an additional 4,805 shares during the period. Johnson & Johnson comprises about 1.9% of Advisor Partners LLC’s investment portfolio, making the stock its 3rd largest position. Advisor Partners LLC’s holdings in Johnson & Johnson were worth $8,021,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the period. Fisher Asset Management LLC lifted its stake in Johnson & Johnson by 3.7% in the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after acquiring an additional 405,517 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Johnson & Johnson by 1.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 11,150,339 shares of the company’s stock worth $1,388,775,000 after acquiring an additional 201,703 shares during the period. Clearbridge Investments LLC lifted its stake in Johnson & Johnson by 3.4% in the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after acquiring an additional 310,831 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Johnson & Johnson by 0.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,948,942 shares of the company’s stock worth $990,041,000 after acquiring an additional 42,144 shares during the period. Hedge funds and other institutional investors own 65.93% of the company’s stock.
JNJ has been the subject of a number of research reports. Cowen and Company reaffirmed an “outperform” rating and issued a $155.00 price objective (up from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research note on Thursday, August 31st. Jefferies Group LLC upped their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $143.70.
Johnson & Johnson (JNJ) opened at $138.87 on Friday. The company has a market cap of $373,694.94, a P/E ratio of 19.48, a P/E/G ratio of 2.83 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 1 year low of $109.32 and a 1 year high of $144.35.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the prior year, the company earned $1.68 EPS. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.42%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
WARNING: “Johnson & Johnson (JNJ) is Advisor Partners LLC’s 3rd Largest Position” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.truebluetribune.com/2017/11/17/johnson-johnson-jnj-is-advisor-partners-llcs-3rd-largest-position-2.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.